Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.

Ellen Weisberg,Xianming Deng,Hwan Geun Choi,Rosemary Barrett,Sophia Adamia,Arghya Ray,Daisy Moreno,Andrew L. Kung,Nathanael S. Gray,James D. Griffin

Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.

2010

Ellen Weisberg
Xianming Deng
Hwan Geun Choi
Rosemary Barrett
Sophia Adamia
Arghya Ray
Daisy Moreno
Andrew L. Kung
Nathanael S. Gray
James D. Griffin

Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML

Keywords:

Genetics
Cancer research
ABL
Philadelphia chromosome
Chronic myelogenous leukemia
Allosteric regulation
Tyrosine-kinase inhibitor
Enzyme inhibitor
Biology
breakpoint cluster region
Imatinib
Enzyme

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations